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Background: The Model of Health Care Empowerment (HCE) defines HCE as the process 
and state of being engaged, informed, collaborative, committed, and tolerant of uncertainty 
regarding health care. We examined the hypothesized antecedents and clinical outcomes of this 
model using data from ongoing human immunodeficiency virus (HIV)-related research. The 
purpose of this paper is to explore whether a new measure of HCE offers direction for under-
standing patient engagement in HIV medical care. Using data from two ongoing trials of social 
and behavioral aspects of HIV treatment, we examined preliminary support for hypothesized 
clinical outcomes and antecedents of HCE in the context of HIV treatment.
Methods: This was a cross-sectional analysis of 12-month data from study 1 (a longitudinal 
cohort study of male couples in which one or both partners are HIV-seropositive and taking HIV 
medications) and 6-month data from study 2, a randomized controlled trial of HIV-seropositive 
persons not on antiretroviral therapy at baseline despite meeting guidelines for treatment. From 
studies 1 and 2, 254 and 148 participants were included, respectively. Hypothesized antecedents 
included cultural/social/environmental factors (demographics, HIV-related stigma), personal 
resources (social problem-solving, treatment knowledge and beliefs, treatment decision-making, 
shared decision-making, decisional balance, assertive communication, trust in providers, personal 
knowledge by provider, social support), and intrapersonal factors (depressive symptoms, positive/
negative affect, and perceived stress). Hypothesized clinical outcomes of HCE included primary 
care appointment attendance, antiretroviral therapy use, adherence self-efficacy, medication 
adherence, CD4+ cell count, and HIV viral load.
Results: Although there was no association observed between HCE and HIV viral load and 
CD4+ cell count, there were significant positive associations of HCE scores with likelihood 
of reporting a recent primary care visit, greater treatment adherence self-efficacy, and higher 
adherence to antiretroviral therapy. Hypothesized antecedents of HCE included higher beliefs 
in the necessity of treatment and positive provider relationships.
Keywords: human immunodeficiency virus, acquired immune deficiency syndrome, health 
care empowerment, adherence, compliance
Background
The model of health care empowerment (HCE) was recently proposed as a struc-
ture for understanding and intervening in how people perceive their participation 
in health care.1 The construct of HCE, defined as the state and process of being 
engaged, informed, committed, tolerant of uncertainty, and collaborative in one’s 
interactions with health care, offers direction for addressing differences in health care 
service utilization and outcomes across a wide range of populations and illnesses. 
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The model hypothesizes that HCE is influenced through 
a dynamic interplay of contextual/environmental factors 
(such as age, race, and stigma), personal resources (such 
as finances, adaptive beliefs about treatment, problem-
solving skills, and trust in providers), and intrapersonal 
processes and states (such as depressive symptoms and 
positive affect).
The treatment of human immunodeficiency virus (HIV) 
and acquired immune deficiency syndrome (AIDS) is one 
example of a medical context that offers a rich opportu-
nity to illustrate the potential applicability of HCE. HIV 
disease in the US and other developed countries is a heavily 
stigmatized condition that disproportionately affects popu-
lations who are economically and socially marginalized, 
including members of racial and ethnic minority groups, gay 
and transgender persons, and people with substance abuse 
histories.2–4 Treatment guidelines and antiretroviral therapy 
options are rapidly changing, and treatments have been his-
torically difficult to tolerate, yet require vigilant adherence to 
prevent development of viral resistance, hastening of disease 
progression, and increased likelihood of the transmission of 
drug-resistant HIV to others.5–7
The purpose of this paper is to present preliminary 
support for the construct of HCE in the context of HIV 
treatment, with a particular emphasis on evaluating whether 
scores on a new measure of HCE are associated with 
hypothesized antecedents and clinical outcomes. Data from 
two ongoing studies of social and behavioral aspects of 
HIV treatment offer empirical evidence and direction for 
future indepth studies of HCE in HIV and other illnesses 
in which patient involvement in ongoing treatment is criti-
cal yet variable.
Materials and methods
A new measure of HCE was included in assessment bat-
teries for two ongoing studies of social and behavioral 
factors of HIV treatment. Study 1 is a longitudinal cohort 
study of male couples in which one or both partners 
are HIV-seropositive and taking antiretroviral therapy. 
Couples are interviewed every 6 months for 2 years. HCE 
was assessed at the 12-month assessment wave as part of 
a comprehensive survey and blood was drawn for CD4+ 
cell count and HIV viral load. Study 2 is a randomized 
controlled trial of HIV-seropositive persons who were not 
on antiretroviral therapy at baseline despite meeting HIV 
treatment guidelines on CD4+ cell count cutoff for initia-
tion of antiretroviral therapy (ie, #500 cells/mm3).8 HCE 
was assessed at the 6-month assessment wave as part of 
a comprehensive survey and blood drawn for CD4+ cell 
count and HIV viral load.
Participants and procedures
Recruitment for both studies included outreach to clinics 
and agencies, and posting of advertisements and flyers in the 
San Francisco Bay area community. HIV-positive serosta-
tus was verified by HIV antibody testing or provision of 
documentation by potential participants, and antiretroviral 
therapy regimens were verified by examination of prescribed 
medication vials or official medication lists from the dispens-
ing pharmacy. Participants provided written informed consent 
and all procedures were approved by the local institutional 
review board at the University of California, San Francisco. 
Combinations of audio computer-assisted self-interviewing 
and computer-assisted personal interviewing were used to 
optimize self-report, to minimize data collection errors, and 
to facilitate efficient data management.9 Screening, data col-
lection, and phlebotomy procedures occurred in private areas 
of research facilities and all participants were compensated 
for their involvement.
Measures
Participants in both studies were asked about general 
demographic information and HIV treatment history, 
including time since HIV diagnosis and past medical treat-
ment details. The following variables were assessed in at 
least one of the two studies and are organized according 
to their hypothesized role as informed by the HCE model 
(Figure 1).
health care empowerment
The 27-item measure of HCE was developed specifically 
by the investigators to assess the five hypothesized domains 
of health care empowerment: informed (five items, sample 
item “I am knowledgeable about my health condition(s)”); 
committed (six items, sample item “I am determined to 
work hard to get the most out of my health care”); col-
laborative (six items, sample item “I think of my health 
care providers as my partners in dealing with my health 
condition[s]”); engaged (five items, sample item “Others 
would probably say that I am a very engaged and active 
patient”); and tolerant of uncertainty (five items, sample 
item “I have learned to live with the uncertainty of my health 
condition”). Responses include five choices ranging from 
“strongly disagree” to “strongly agree” and a global score 
is created by summing responses to all individual items. 
Cronbach’s alphas of 0.94 and 0.96 were calculated for 
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study 1 and study 2, respectively, demonstrating acceptable 
internal reliability, and 6-month test-reliability estimates of 
0.73 were available for study 1. This is the first publication 
to use this new measure.
hypothesized clinical outcomes of hCE
To examine hypothesized proximal and downstream clini-
cal consequences of HCE, the following data were analyzed 
(study 1 and/or study 2 indicate in which study the measure 
was administered), and reported alphas are for the current 
samples.
•	 Primary care appointment attendance (study 1 and 
study 2): failure to consistently attend clinic appoint-
ments has been linked to poor virological control.10,11 We 
documented the time since most recent primary care visit 
and, for consistency between the two studies, classified 
all participants as having a primary care visit within the 
prior 3 months or not.
•	 Antiretroviral therapy use (study 2): whether participants 
had initiated antiretroviral therapy during the follow-up 
period was documented for study 2 participants, all of 
whom met criteria for antiretroviral therapy initiation per 
HIV treatment guidelines8 at study enrollment.
•	 Adherence self-efficacy (study 1 and study 2): adherence 
self-efficacy, or confidence in one’s ability to comply 
with a treatment plan, has been consistently linked to 
medication adherence over time.12,13 The HIV- Adherence 
Self Eff icacy Scale (HIV-ASES) assesses patient 
confidence in carrying out health-related behaviors 
(eg, asking physician questions, keeping appointments, 
adhering to medication).14 This measure includes two 
subscales, ie, integration and perseverance; α = 0.91 and 
0.78, respectively, for study 1, and α = 0.91 and 0.65, 
respectively, for study 2.
•	 Medication adherence (study 1 and study 2): adherence 
to antiretroviral medications was assessed using two well 
validated measures of self-report. The adherence measure 
developed to assess adherence in the AIDS Clinical Trials 
Group15 solicits detailed information about self-reported 
adherence over the previous 3 days. Adherence scores 
on this scale have been correlated with viral load.15,16 
Second, a visual analog scale was administered,17 which 
assesses 30-day adherence reporting separately for each 
drug along a continuum anchored by “0%” to “100%.” 
This measure has been shown to be correlated with 
other adherence measures, such as electronic medica-
tion monitors.18,19 The 3-day adherence measure was 
dichotomized as 100% versus ,100% adherence and 
the 30-day visual analog scale adherence is reported as 
a continuous variable.
•	 CD4+ cell count and viral load (study 1 and study 2): HIV 
viral load was determined using the COBAS®  AmpliPrep/
COBAS® TaqMan® HIV test kit (Roche Molecular 
 Systems Inc, Pleasanton, CA), which has a threshold for 
undetectability #20 copies/mL. A detectable viral load 
indicates incomplete viral suppression, or inadequately 
controlled HIV infection. CD4+ cell count provides a 
gauge of immune functioning, with lower counts typi-
cally indicating longer infection and/or greater immune 
system deterioration. In healthy persons, the normal range 
of CD4+ cell count is 500–1500 cells/mm3 of blood, and 
current HIV treatment guidelines recommend offering 
antiretroviral therapy to all HIV-seropositive persons with 
a CD4+ cell count below 500.8
hypothesized antecedents of hCE
HCE is hypothesized to be related to three categories 
of variables, ie, cultural/social/environmental factors, 
Intrapersonal 
factors
Negative affect
Positive affect
Contextual/environmental 
factors
Sociodemographics
Perceived stigma
Personal resources
Problem solving skills
Social support
Communication skills
Financial stability
Positive provider relationships
Knowledge, beliefs and preferences
Health care
empowerment
Clinical outcomes
Adherence and engagement
CD4+ cell count
Viral load
Figure 1 hypothesized mode1 of health care empowerment.
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personal resources (both material and psychological), and 
intrapersonal factors.
Cultural/social/environmental factors
Demographics (study 1 and study 2): including age, gender, 
race, and ethnicity were assessed via interview. HIV-related 
stigma (study 2) is believed to be a strong driver of HIV 
risk and treatment outcomes, and is often cited when 
discussing the sources of HIV-related disparities.20–27 HIV 
stigma (study 2) was assessed using the four-item distancing 
subscale of a stigma scale developed by Sowell, which 
assesses perceived distancing from others due to HIV-positive 
status (α = 0.90).26,28
Personal resources
•	 Social problem-solving (study 1): investigated using 
the Social Problem-Solving Inventory-Revised ques-
tionnaire,29,30 a 25-item, self-administered question-
naire that assesses problem orientation (negative 
and positive), problem-solving styles (avoidant and 
impulsive/careless), and rational problem-solving 
skills. The measure has been widely used, has been 
predictive of health and risk behaviors,31 and has 
shown meaningful relationships with antiretroviral 
therapy adherence in our prior work.32 As before, we 
combined the positive problem-solving scores into a 
constructive problem-solving scale (α = 0.82) and the 
negative problem-solving scales into a dysfunctional 
problem-solving scale (α = 0.85).
•	 Treatment knowledge (study 2): a 16-item HIV treatment 
knowledge assessment was administered, with higher 
scores reflecting more accurate knowledge of aspects 
of treatment such as adherence, side effects, and drug 
resistance (α = 0.83).33
•	 Treatment beliefs (study 1 and study 2): assessed using 
the HIV version of the Beliefs About Medications 
Questionnaire,34 which includes subscales of treatment 
necessity (α = 0.84 and 0.82) and treatment concerns 
(α = 0.66 and 0.72).
•	 Preference for treatment decision-making (study 1): The 
6-item Autonomy Preference Index specifically assesses 
patient preferences for shared medical decision-making 
(α = 0.67), with good evidence of concurrent and criterion 
validity.35 Higher scores reflect stronger preferences for 
patient involvement in treatment decision-making.
•	 Opportunity for shared decision-making (study 1): The 
3-item Decision-Making Opportunity Scale36 assesses 
how often a provider discusses the pros and cons of 
each medical care choice, elicits statements of patient 
preference, and takes patient preference into account 
when making treatment decisions (α = 0.85). Higher 
scores indicate a patient’s perception of greater opportu-
nity for involvement, as enabled by the provider.
•	 Decisional balance (study 1 and study 2): A single item 
by Beach et al37 assessing decisional balance preference 
was administered, ie, “Which best describes how deci-
sions about your HIV treatment are made during your 
visits with your HIV care provider?” Response choices 
are 0 (“Provider makes most or all of the decisions”) 
1 (“Provider and I make the decisions together”), and 
2 (“I make most or all of the decisions”). Higher scores 
indicate a patient’s perception of greater involvement in 
treatment decisions.
•	 Assertive communication (study 2): assessed with the 
5-item Patient Communication Index scale of the Patient 
Reactions Questionnaire, with higher scores indicating 
greater difficulty with assertive communication with 
providers (α = 0.92).38
•	 Positive provider interactions (study 2): The Positive 
Patient-Provider Interaction scale39 assesses the degree 
to which recent patient-provider interactions were seen 
as constructive by patients (α = 0.95).
•	 Trust in providers (study 2): The 11-item Trust in 
Physician Scale40 assesses patients’ interpersonal trust in 
their provider and has been used in the context of HIV 
treatment (α = 0.74).41
•	 Personal knowledge by provider (study 1 and study 2): 
A single item, ie, “My provider really knows me as a 
person.” In previous work, higher agreement with this 
statement was linked with greater antiretroviral therapy 
uptake and adherence.37
•	 Social support (study 2): The Social Provisions Scale42 
assesses level, type, and perceived satisfaction with 
social support from one’s social network. For the current 
analysis, we used the overall score, with higher values rep-
resenting greater perceived social support (α = 0.91).
Intrapersonal factors
•	 Depressive symptoms (study 1 and study 2): the Center 
for Epidemiologic Studies Depression Scale (CES-D)43 
was administered to measure depressed mood in the past 
week. The CES-D consists of 20 items rated on a 4-point 
scale according to how frequently they were experienced 
in the previous week (α = 0.92 and 0.92).
•	 Positive and negative affect (study 1): We administered 
the Differential Emotions Scale44,45 which assesses 
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60 emotions of varied valence rated on a 5-point scale 
according to how frequently they were experienced in 
the past week. The scale was scored for total positive 
(α = 0.90) and negative affect (α = 0.86).
•	 Perceived stress (study 2): Cohen’s Perceived Stress 
Scale46 assesses the degree to which a person describes 
situations in the prior month as stressful. A total score 
is provided by summing ratings on a 5-point scale 
(α = 0.86), with higher scores indicating greater reports 
of distress.
Data analysis
The reported analyses were exploratory and guided by 
the model of HCE.1 The first analytic goal was to explore 
unadjusted associations of HCE with hypothesized clini-
cal outcomes of HCE, eg, HIV biomarker measures of 
adherence as well as self-reported subjective measures 
of adherence self-efficacy. These include proximal and 
distal or downstream indicators of active, empowered 
engagement in medical treatment. The second goal was 
to use existing data to explore bivariate and multivariate 
associations of hypothesized antecedents of HCE. For each 
study, initial analyses described frequencies for categorical 
variables and measures of central tendency (median) and 
variability (standard deviations) for continuous variables. 
Bivariate analyses correlated HCE scale scores with clinical 
biomarker and self-report data, contextual/environmental 
factors, personal resource factors, and intrapersonal factors. 
Contextual/environmental, personal, and intrapersonal factors 
for which bivariate associations with HCE were significant at 
P , 0.25 were included in multivariable regression models 
explaining HCE in each study.47 Beginning with the least 
significant explanatory variable, the hypothesized contextual/
environmental, personal, and intrapersonal antecedents were 
removed until all remaining correlates in adjusted analyses 
were significant at P , 0.05 (ie, backward elimination).48 
SAS version 9 (SAS Institute Inc, Cary, NC) was used to 
generate descriptive statistics; Mplus version 6 (Muthén and 
Muthén, Los Angeles, CA) was used to generate bivariate 
and adjusted analysis results via full information maximum 
likelihood, which makes use of all available information in 
the data to obtain optimal parameter estimates and standard 
errors when one or more cases have incomplete data.49 This 
method prevents different sample sizes being used for the 
backward elimination procedure for multivariable regression 
analyses due to some participants missing information on 
one or more measures. Bivariate (ie, unadjusted) correlations 
were reported using the r statistic. Adjusted coefficients from 
multivariable regression models were reported using the 
standardized regression coefficient, β, to quantify the amount 
of change per standard deviation in HCE as a function of 
each explanatory variable in the context of other significant 
correlates of HCE.
Results
Sample characteristics for participants in both studies are 
provided in Table 1. Study 2 participants included a greater 
proportion of African Americans, reported lower income 
and education, and were more likely to report histories of 
homelessness and injection drug use. Due to differences in 
study eligibility criteria, study 2 included more women and 
heterosexuals, and study 1 participants were more likely 
to have higher CD4+ cell counts and an undetectable viral 
load.
hypothesized clinical outcomes of hCE
Examination of hypothesized clinical outcomes of HCE 
in study 1 resulted in significant positive associations of 
HCE scores with likelihood of reporting a primary care 
visit in the previous 3 months (r = 0.29, P = 0.001), greater 
adherence self-efficacy integration (r = 0.39, P , 0.001) 
and perseverance scores (r = 0.33, P , 0.001), higher 3-day 
antiretroviral therapy adherence (r = 0.21, P = 0.004), and 
higher 30-day antiretroviral therapy adherence (r = 0.23, 
P = 0.001). In study 2, there was a similar pattern, in 
which higher HCE scores were reported by those report-
ing primary care visits in the prior 3 months (r = 0.25, 
P = 0.003), those with higher adherence self-efficacy 
integration scores (r = 0.26, P , 0.001), and those with 
higher 30-day antiretroviral therapy adherence reports 
(r = 0.27, P = 0.002). Unlike study 1, there was no asso-
ciation between HCE scores and adherence self-efficacy 
perseverance and 3-day antiretroviral therapy adherence. 
HCE was not associated with CD4 or viral load in either 
sample (see Table 2).
hypothesized antecedents of hCE
Although there was a positive bivariate relationship between 
age and higher HCE scores in study 1 (r = 0.15, P = 0.01), 
none of the contextual/social/background variables were 
significant in the adjusted models for either study 1 or 
study 2 (see Tables 3 and 4). In the adjusted model for 
study 1, several personal resource factors were associated 
with higher HCE, including higher constructive problem 
solving (β = 0.17, P = 0.01) and lower dysfunctional 
problem solving (β = −0.28, P = 0.01), higher beliefs in the 
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necessity of treatment (β = 0.14, P = 0.02), higher reports 
of involvement in treatment decision-making (β = 0.19, 
P , 0.001), higher scores on the Autonomy Preference 
Index (β = 0.22, P , 0.001), and perceptions that the pro-
vider knows the patient as a person (β = 0.27, P , 0.001). 
In study 2, adjusted analyses revealed a positive association 
with beliefs in treatment necessity (β = 0.27, P = 0.01) and 
perceptions of recent positive provider interactions (β = 0.25, 
P = 0.004), and an association of lower HCE with greater 
difficulty with assertive communication with providers 
(β = −0.31, P , 0.001).
In study 1 adjusted analyses, higher HCE scores were 
associated with lower reported symptoms of depression 
(β = 0.25, P = 0.001) and higher reports of positive emotion 
Table 1 Participant characteristics
Study 1 (n = 254) Study 2 (n = 148) P
Age, mean (SD), years 45.4 ± 9.6 44.5 ± 8.1 0.51
Percent male 254 (100.0) 121 (81.8) ,0.0001
race – – ,0.0001
 Black/African American 45 (17.8) 73 (49.3) –
 White 135 (53.2) 48 (32.4) –
 Other 74 (29.1) 27 (18.2) –
hispanic ethnicity 46 (18.1) 16 (10.8) 0.05
Sexual orientation – – ,0.0001
 heterosexual 2 (0.8) 46 (31.1) –
 homosexual 229 (90.2) 72 (48.7) –
 Bisexual/other 23 (9.1) 30 (20.3) –
Education – – ,0.0001
  ,high school 12 (4.7) 32 (21.6) –
 high school 64 (25.2) 59 (39.9) –
 Some college 74 (29.1) 42 (28.4) –
 College graduate 104 (40.9) 15 (10.1) –
Income ,US$20,000 134 (52.8) 120 (88.5) ,0.0001
Ever homeless or lived in shelter 71 (28.0) 108 (74.0) ,0.0001
history of injection drug use 82 (32.3) 73 (49.3) 0.0007
CD4 count – – ,0.0001
 ,200 19 (7.5) 45 (30.4) –
 200–500 93 (36.6) 84 (56.8) –
 .500 142 (55.9) 19 (12.8) –
Viral load undetectable (%) 134 (53.4) 20 (14.0) ,0.0001
Months since hIV+ mean (SD) 154.5 (94.4) 135.6 (89.6) 0.05
health care empowerment, mean (SD) 113.7 (12.2) 103.3 (19.0) ,0.0001
Note: Comparisons were made using Pearson’s Chi-square test for binary, nominal, and ordinal variables and the Wilcoxon rank-sum test for continuous variables.
Abbreviations: SD, standard deviation; HIV, human immunodeficiency virus.
Table 2 hypothesized clinical correlates of health care empowerment
Clinical correlate Study 1 Study 2
r (95% CI) P r (95% CI) P
On ArT – – 0.07 (−0.10, 0.23) 0.43
Primary care appointment last 3 months 0.29 (0.12, 0.46) 0.001 0.25 (0.08, 0.41) 0.003
Adherence self-efficacy: integration 0.39 (0.28, 0.49) ,0.001 0.26 (0.12, 0.41) ,0.001
Adherence self-efficacy: perseverance 0.33 (0.22, 0.43) ,0.001 0.08 (−0.10, 0.27) 0.38
Three-day 100% ArT adherence 0.21 (0.07, 0.35) 0.004 0.14 (−0.07, 0.34) 0.19
Thirty-day ArT adherence 0.23 (0.10, 0.37) 0.001 0.27 (0.10, 0.43) 0.002
CD4+ cell count 0.02 (−0.10, 0.14) 0.70 0.14 (−0.02, 0.30) 0.08
Detectable viral load −0.08 (−0.21, 0.04) 0.19 0.03 (−0.16, 0.20) 0.79
Notes: n = 254 for study 1; n = 148 for study 2. All coefficients were estimated using full-information maximum likelihood in Mplus 6. All coefficients are standardized with 
binary correlates standardized on health care empowerment only and continuous correlates standardized on both health care empowerment and the correlates; coefficients 
may be interpreted as bivariate correlations. All inferences were generated using robust variance estimation (Mplus estimator MLR), with confidence intervals and test 
statistics additionally corrected for nesting of participants within couples in study 1.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; MLR, maximum likelihood with robust standard errors and test statistics.
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(β = 0.28, P , 0.001). Depression and perceived stress were 
not associated with HCE scores in study 2.
Discussion
Findings from the two studies provide support for the model 
of health care empowerment in the context of HIV treatment. 
Consistent with the hypothesized role of HCE, greater patient 
empowerment was associated with reports of active participa-
tion in HIV care and perceived confidence in ability to adhere 
to treatment and self-reports of recent medication adherence. 
The association between HCE and laboratory markers of 
clinical status did not reach statistical significance, but this 
may be due to a restricted range on these variables, limited 
sample sizes, and the specific eligibility criteria regarding 
antiretroviral therapy use in the two studies.
The resulting correlates of HCE support a central role for 
knowledge, skills, provider relationships, and psychological 
well being in association with patient empowerment. From a 
research perspective, these findings offer direction for future 
in-depth studies of the role of empowerment. From a clinical 
perspective, findings suggest that providers who make efforts 
to get to know their patients beyond their clinical presentation, 
who strive to respect and foster patient autonomy, and who 
make concrete efforts to involve patients in decision-making 
may be effective in fostering health care empowerment in 
their patients. Interventions designed to improve patient 
skills in problem solving and assertive communication with 
providers edify treatment knowledge and reinforce a solid 
understanding for the need for prescribed treatments, and 
detect and treat depressive symptoms while fostering positive 
affect may promote greater patient empowerment and thus 
more productive engagement in care. Such improvements in 
empowerment may then facilitate better treatment utilization 
and adherence to antiretroviral therapy, resulting in more 
effective virological control and decreased HIV transmis-
sion to others.50,51
The pattern of hypothesized antecedents of HCE suggests 
no direct statistical association of contextual factors with 
empowerment scores, including stigma. Consistent with the 
model of HCE, it may be that these factors operate indirectly 
on empowerment by affecting other elements in the model, 
such as personal resources (eg, treatment knowledge) and 
intrapersonal factors (eg, depression). It is also likely that 
the samples recruited were not representative of the larger 
Table 3 hypothesized antecedents of health care empowerment (study 1, n = 254)
Unadjusted Adjusted
r (95% CI) P β (95% CI) P
Contextual/environmental factors
 race/ethnicity Χ2(3) = 1.91a 0.59 – –
 White (non-hispanic, reference) – – – –
 Black (non-hispanic) 0.04 (−0.07, 0.15) 0.47 – –
 hispanic −0.01 (−0.13, 0.11) 0.87 – –
 Other race −0.11 (−0.27, 0.05) 0.19 – –
 Age 0.15 (0.04, 0.26) 0.01 – –
Personal resource factors
 Income ,US$20,000 0.04 (−0.09, 0.16) 0.55 – –
 relationship satisfaction (CSI) 0.05 (−0.09, 0.18) 0.52 – –
 Social problem solving (constructive) 0.39 (0.26, 0.52) ,0.001 0.17 (0.05, 0.29) 0.01
 Social problem solving (dysfunctional) −0.36 (−0.50, -0.21) ,0.001 −0.28 (−0.43, −0.12) ,0.001
 Need for BMQ 0.21 (0.10, 0.33) ,0.001 0.14 (0.02, 0.25) 0.02
 BMQ concerns −0.05 (−0.18, 0.08) 0.49 – –
 Shared decision-making 0.26 (0.12, 0.40) ,0.001 0.19 (0.09, 0.30) ,0.001
 Provider knows me as a person 0.32 (0.20, 0.43) ,0.001 0.27 (0.17, 0.37) ,0.001
 Autonomy preference index 0.24 (0.09, 0.39) 0.001 0.22 (0.10, 0.34) ,0.001
 Decision-making opportunity scale 0.39 (0.21, 0.56) ,0.001 – –
Intrapersonal factors
 Depression −0.18 (−0.30, −0.06) 0.004 0.25 (0.10, 0.41) 0.001
 DES positive emotion 0.34 (0.22, 0.47) ,0.001 0.28 (0.13, 0.44) ,0.001
 DES negative emotion −0.16 (−0.28, −0.04) 0.01 – –
Notes: All coefficients were estimated using full-information maximum likelihood in Mplus 6. All coefficients are standardized with binary correlates standardized on health 
care empowerment only and continuous correlates standardized on both health care empowerment and the correlates. Unadjusted coefficients may be interpreted as bivariate 
correlations; adjusted coefficients may be interpreted as standardized regression coefficients. All inferences were generated using robust variance estimation (Mplus estimator 
MLR) with confidence intervals and test statistics corrected for nesting of participants within couples. aJoint Wald significance test of race dummy variables.
Abbreviations: CSI, Couple Satisfaction Index; DES, Differential Emotions Scale; BMQ, Beliefs About Medications Questionnaire; MLr, maximum likelihood with robust 
standard errors and test statistics.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
401
health care empowerment and hIV treatment
Patient Preference and Adherence 2012:6
population on such measures as HIV stigma; those who are 
willing to enroll in ongoing research related to HIV might 
not be as sensitive or affected by HIV stigma as others who 
chose not to enroll. The limited sample sizes in this explor-
atory work precluded larger model testing through such 
procedures as structural equation modeling which could test 
simultaneous moderator and mediator effects.
Although generally consistent results were found between 
the two studies and the results were in the expected direc-
tions, the findings should be generalized with caution. The 
studies used convenience samples from one geographic 
area and relied primarily on self-reported measures, such 
as appointment attendance and medication adherence. Data 
are cross-sectional and thus cannot be used to determine 
causality. The 3-month time frame for the primary care visit 
variable may be too restrictive, because patients in stable 
clinical care may have less frequent but regular provider 
visits. The relatively modest sample sizes and limited vari-
ability of gender, age, race, and ethnicity preclude specific 
analysis of subgroups, and findings should thus be considered 
preliminary. Nonetheless, the pattern of findings across the 
two studies offers encouragement for further investigation 
of the model of health care empowerment.
In summary, our results reveal a rough map of the terrain 
of health care empowerment. Future investigations are needed 
to refine the measurement of the construct, to form and test 
new hypotheses, and to evaluate the fit of the construct and 
the model of health care empowerment in other illness set-
tings and across cultures.
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Table 4 hypothesized antecedents of health care empowerment, study 2 (n = 148)
Unadjusted Adjusted
r (95% CI) P β (95% CI) P
Contextual/environmental factors
 race/ethnicity Χ2(2) = 00.14a 0.93 – –
 White (non-hispanic, reference) – – – –
 Black (non-hispanic) −0.02 (−0.18, 0.14) 0.81 – –
 hispanic and other races −0.01 (−0.16, 0.14) 0.92 – –
 Age −0.04 (−0.19, 0.12) 0.65 – –
 Female gender −0.03 (−0.21, 0.16) 0.78 – –
 hIV stigma (distancing) −0.03 (−0.21, 0.14) 0.73 – –
Personal resource factors
 Income ,US$10,000 0.16 (0.02, 0.30) 0.03 – –
 Social support (social provisions scale) 0.40 (0.27, 0.53) ,0.001 – –
 Treatment knowledge 0.31 (0.14, 0.49) ,0.001 – –
 Trust in provider 0.33 (0.19, 0.47) ,0.001 – –
 Need for BMQ 0.30 (0.04, 0.55) 0.02 0.27 (0.07, 0.48) 0.01
 BMQ concerns −0.23 (−0.42, −0.03) 0.02 – –
 Shared decision-making −0.08 (−0.23, 0.08) 0.35 – –
 Provider knows me as a person 0.22 (0.06, 0.38) 0.01 – –
 Patient reactions assessment −0.48 (−0.62, −0.33) ,0.001 −0.31 (−0.49, −0.14) ,0.001
 Positive provider interactions 0.43 (0.30, 0.56) ,0.001 0.25 (0.08, 0.42) 0.004
Intrapersonal factors
 Depression −0.20 (−0.36, −0.03) 0.02 – –
 Perceived stress −0.09 (−0.25, 0.08) 0.30 – –
Notes: All coefficients were estimated using full-information maximum likelihood in Mplus 6. All coefficients are standardized with binary correlates standardized on health 
care empowerment only and continuous correlates standardized on both health care empowerment and the correlates. Unadjusted coefficients may be interpreted as 
bivariate correlations; adjusted coefficients may be interpreted as standardized regression coefficients. All inferences were generated using robust variance estimation (Mplus 
estimator MLr). aJoint Wald significance test of race dummy variables.
Abbreviations: CI, confidence interval; BMQ, Beliefs About Medications Questionnaire; HIV, human immunodeficiency virus; MLR, maximum likelihood with robust 
standard errors and test statistics.
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